Assembly Biosciences Files 8-K

Ticker: ASMB · Form: 8-K · Filed: 2025-06-25T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, financials

Related Tickers: ASMB

TL;DR

ASMB filed an 8-K, likely routine updates on financials/events.

AI Summary

Assembly Biosciences, Inc. filed an 8-K on June 25, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not detail specific transactions or events but serves as a notification of these categories being addressed. The company, formerly Ventrus Biosciences Inc., is incorporated in Delaware and headquartered in South San Francisco, California.

Why It Matters

This 8-K filing indicates that Assembly Biosciences is making required disclosures regarding other events and financial statements, which is a standard regulatory step for public companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not contain information about significant new risks or material adverse events.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Assembly Biosciences, Inc. in this 8-K filing?

The filing does not specify the nature of the 'Other Events' beyond listing it as an item information category.

When was Assembly Biosciences, Inc. formerly known as Ventrus Biosciences Inc.?

The date of the name change from Ventrus Biosciences Inc. to Assembly Biosciences, Inc. was February 11, 2008.

What is the primary business of Assembly Biosciences, Inc. according to its SIC code?

Assembly Biosciences, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).

Where are Assembly Biosciences, Inc.'s principal executive offices located?

The principal executive offices are located at Two Tower Place, 7th Floor, South San Francisco, California 94080.

What is the fiscal year end for Assembly Biosciences, Inc.?

The fiscal year end for Assembly Biosciences, Inc. is December 31 (1231).

From the Filing

0000950170-25-089949.txt : 20250625 0000950170-25-089949.hdr.sgml : 20250625 20250625160530 ACCESSION NUMBER: 0000950170-25-089949 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20250625 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250625 DATE AS OF CHANGE: 20250625 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 251073673 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 8-K 1 asmb-20250625.htm 8-K 8-K false 0001426800 0001426800 2025-06-25 2025-06-25     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)       Two Tower Place , 7th Floor , South San Francisco , California 94080 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (833) 509-4583 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001   ASMB   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events. On June 25, 2025, Assembly Biosciences, Inc. (the "Company") issued a press release announcing topline results from the Phase 1b evaluating ABI-4334, an investigational next-generation capsid assembly modulator in participants with chronic hepatitis B virus infection. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits .   Exhibit Number Description 99.1 Press Release dated June 25, 2025.  104 Cover Page Interactive Data File (embedded within the Inline XBRL document)   1   SIGNATURES Pursuant to the requirements of the Securi

View on Read The Filing